EP2928462A4 - METHOD FOR ADMINISTERING COMPOUNDS WITH DOCOSAPENTAIC ACID - Google Patents

METHOD FOR ADMINISTERING COMPOUNDS WITH DOCOSAPENTAIC ACID

Info

Publication number
EP2928462A4
EP2928462A4 EP13861305.4A EP13861305A EP2928462A4 EP 2928462 A4 EP2928462 A4 EP 2928462A4 EP 13861305 A EP13861305 A EP 13861305A EP 2928462 A4 EP2928462 A4 EP 2928462A4
Authority
EP
European Patent Office
Prior art keywords
methods
docosapentaenoic acid
administering compositions
administering
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP13861305.4A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP2928462A2 (en
Inventor
George Bobotas
Abdel Aziz Fawzy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Matinas Biopharma Inc
Original Assignee
Matinas Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Matinas Biopharma Inc filed Critical Matinas Biopharma Inc
Publication of EP2928462A2 publication Critical patent/EP2928462A2/en
Publication of EP2928462A4 publication Critical patent/EP2928462A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23B—PRESERVATION OF FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES; CHEMICAL RIPENING OF FRUIT OR VEGETABLES
    • A23B20/00—Preservation of edible oils or fats
    • A23B20/30—Preservation of other edible oils or fats, e.g. shortenings or cooking oils
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS OR COOKING OILS
    • A23D9/00—Other edible oils or fats, e.g. shortenings or cooking oils
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4875—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11B—PRODUCING, e.g. BY PRESSING RAW MATERIALS OR BY EXTRACTION FROM WASTE MATERIALS, REFINING OR PRESERVING FATS, FATTY SUBSTANCES, e.g. LANOLIN, FATTY OILS OR WAXES; ESSENTIAL OILS; PERFUMES
    • C11B5/00—Preserving by using additives, e.g. anti-oxidants
    • C11B5/0007—Organic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Diabetes (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Zoology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Botany (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
EP13861305.4A 2012-12-06 2013-12-06 METHOD FOR ADMINISTERING COMPOUNDS WITH DOCOSAPENTAIC ACID Withdrawn EP2928462A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261734331P 2012-12-06 2012-12-06
US201361780948P 2013-03-13 2013-03-13
PCT/US2013/073714 WO2014089511A2 (en) 2012-12-06 2013-12-06 Methods of administering compositions comprising docosapentaenoic acid

Publications (2)

Publication Number Publication Date
EP2928462A2 EP2928462A2 (en) 2015-10-14
EP2928462A4 true EP2928462A4 (en) 2016-06-01

Family

ID=50884050

Family Applications (3)

Application Number Title Priority Date Filing Date
EP13861305.4A Withdrawn EP2928462A4 (en) 2012-12-06 2013-12-06 METHOD FOR ADMINISTERING COMPOUNDS WITH DOCOSAPENTAIC ACID
EP21170003.4A Withdrawn EP3888646A1 (en) 2012-12-06 2013-12-06 Omega-3 pentaenoic acid compositions and methods of use
EP13861394.8A Withdrawn EP2929041A4 (en) 2012-12-06 2013-12-06 OMEGA-3-PENTAIC ACID COMPOSITIONS AND METHODS OF USE

Family Applications After (2)

Application Number Title Priority Date Filing Date
EP21170003.4A Withdrawn EP3888646A1 (en) 2012-12-06 2013-12-06 Omega-3 pentaenoic acid compositions and methods of use
EP13861394.8A Withdrawn EP2929041A4 (en) 2012-12-06 2013-12-06 OMEGA-3-PENTAIC ACID COMPOSITIONS AND METHODS OF USE

Country Status (9)

Country Link
EP (3) EP2928462A4 (enrdf_load_stackoverflow)
JP (4) JP2016501249A (enrdf_load_stackoverflow)
KR (3) KR20210059779A (enrdf_load_stackoverflow)
CN (4) CN104937103A (enrdf_load_stackoverflow)
AU (7) AU2013354969A1 (enrdf_load_stackoverflow)
CA (2) CA2894366A1 (enrdf_load_stackoverflow)
IN (2) IN2015DE05009A (enrdf_load_stackoverflow)
MX (2) MX2015007085A (enrdf_load_stackoverflow)
WO (2) WO2014089511A2 (enrdf_load_stackoverflow)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101568665B1 (ko) 2015-07-21 2015-11-12 디와이오토 주식회사 모터의 맥동 전류를 증가시키는 브러시 구조
US20190346459A1 (en) * 2016-06-28 2019-11-14 Nestec S.A. Biomarkers of blood-brain barrier dysfunction
JP2018168139A (ja) * 2016-10-21 2018-11-01 マルハニチロ株式会社 ｎ−３系不飽和脂肪酸を含む中性脂肪値の低減または上昇抑制用の組成物、並びに該組成物の製造におけるｎ−３系不飽和脂肪酸の使用
JP7099821B2 (ja) * 2017-12-20 2022-07-12 ポッカサッポロフード＆ビバレッジ株式会社 Ｐｃｓｋ９阻害剤及びコレステロール代謝改善用食品組成物
EP3586640A1 (en) 2018-06-21 2020-01-01 Nuseed Pty Ltd Dha enriched polyunsaturated fatty acid compositions
EP3586642A1 (en) 2018-06-21 2020-01-01 Nuseed Pty Ltd Ala enriched polyunsaturated fatty acid compositions

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1714564A1 (en) * 2005-04-21 2006-10-25 N.V. Nutricia Method for treatment and prevention of respiratory insufficiency
WO2008032949A1 (en) * 2006-09-14 2008-03-20 Ilshin Wells Co., Ltd. Glyceride oil composition from fish oil and preparation method thereof
US20110071090A1 (en) * 2009-03-11 2011-03-24 Stable Solutions Llc Method of mitigating adverse drug events using omega-3-fatty acids as a parenteral therapeutic drug vehicle
WO2013192109A1 (en) * 2012-06-17 2013-12-27 Matinas Biopharma, Inc. Omega-3 pentaenoic acid compositions and methods of use

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8819110D0 (en) 1988-08-11 1988-09-14 Norsk Hydro As Antihypertensive drug & method for production
GB9901809D0 (en) * 1999-01-27 1999-03-17 Scarista Limited Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
GB0016045D0 (en) 2000-06-29 2000-08-23 Laxdale Limited Therapeutic combinations of fatty acids
JP2002125618A (ja) * 2000-10-30 2002-05-08 Katsuyuki Wakatsuki 健康食品
WO2007058523A1 (en) 2005-11-17 2007-05-24 N.V. Nutricia Composition with docosapentaenoic acid
US8877465B2 (en) * 2006-07-05 2014-11-04 Photonz Corporation Limited Production of ultrapure EPA and polar lipids from largely heterotrophic culture
ES2881885T3 (es) * 2009-03-09 2021-11-30 Basf As Composiciones que comprenden una mezcla de aceites de ácidos grasos que comprende EPA y DHA en forma de ácido libre y un tensioactivo, y procedimientos y usos de las mismas
US8241672B2 (en) * 2009-03-11 2012-08-14 Stable Solutions Llc Omega-3 enriched fish oil-in-water parenteral nutrition emulsions
PL3278665T3 (pl) * 2009-04-29 2021-02-22 Amarin Pharmaceuticals Ireland Limited Stabilna kompozycja farmaceutyczna i sposoby jej zastosowania
CA3026006C (en) * 2009-06-15 2021-09-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
CA2827555A1 (en) * 2011-02-16 2012-08-23 Pivotal Therapeutics, Inc. Cholesterol absorption inhibitor (azetidinone) and omega 3 fatty acids (epa, dha, dpa) for the reduction of cholesterol and for the reduction of cardiovascular events
CA2827585A1 (en) * 2011-02-16 2012-08-23 Pivotal Therapeutics, Inc. Statin and omega 3 fatty acids (epa, dha and dpa) for use in cardiovascular diseases

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1714564A1 (en) * 2005-04-21 2006-10-25 N.V. Nutricia Method for treatment and prevention of respiratory insufficiency
WO2008032949A1 (en) * 2006-09-14 2008-03-20 Ilshin Wells Co., Ltd. Glyceride oil composition from fish oil and preparation method thereof
US20110071090A1 (en) * 2009-03-11 2011-03-24 Stable Solutions Llc Method of mitigating adverse drug events using omega-3-fatty acids as a parenteral therapeutic drug vehicle
WO2013192109A1 (en) * 2012-06-17 2013-12-27 Matinas Biopharma, Inc. Omega-3 pentaenoic acid compositions and methods of use

Also Published As

Publication number Publication date
AU2017232203A1 (en) 2017-10-12
AU2018229440A1 (en) 2018-10-04
JP2019172697A (ja) 2019-10-10
EP3888646A1 (en) 2021-10-06
CN104937103A (zh) 2015-09-23
IN2015MU01505A (enrdf_load_stackoverflow) 2016-05-27
CA2894183A1 (en) 2014-06-12
AU2013354979A1 (en) 2015-06-11
KR20150103009A (ko) 2015-09-09
KR20210059779A (ko) 2021-05-25
EP2929041A4 (en) 2016-06-08
CN104902888A (zh) 2015-09-09
KR20150103671A (ko) 2015-09-11
AU2021201865A1 (en) 2021-04-22
AU2020203658A1 (en) 2020-06-25
AU2013354969A1 (en) 2015-06-11
EP2929041A1 (en) 2015-10-14
EP2928462A2 (en) 2015-10-14
WO2014089501A1 (en) 2014-06-12
CN112107570A (zh) 2020-12-22
WO2014089511A3 (en) 2014-07-31
JP2021120407A (ja) 2021-08-19
JP2016501248A (ja) 2016-01-18
MX2015007082A (es) 2016-01-12
JP2016501249A (ja) 2016-01-18
CN113274378A (zh) 2021-08-20
CA2894366A1 (en) 2014-06-12
WO2014089511A2 (en) 2014-06-12
JP6881893B2 (ja) 2021-06-02
AU2019216634A1 (en) 2019-09-05
MX2015007085A (es) 2016-01-12
IN2015DE05009A (enrdf_load_stackoverflow) 2015-12-18

Similar Documents

Publication Publication Date Title
EP2934505A4 (en) EICOSAPENTAIC ACID (EPA) FORMULATIONS
EP2819788A4 (en) XTEN CONJUGATE COMPOSITIONS AND METHOD FOR THE PRODUCTION THEREOF
EP2839035A4 (en) NUCLEINSÄUREPROBENPRÄPARAT
EP2971167A4 (en) COMPOSITIONS AND METHODS OF TARGETING NUCLEIC ACIDS BY NUCLEIC ACIDS
EP2552216A4 (en) DERIVATIVES OF 1-AMINO-2-CYCLOPROPYLETHYLBORONIC ACID
EP2768539A4 (en) ANTIMICROBIAL FORMULATIONS WITH PELARGONIC ACID
EP2861787A4 (en) COMPOSITIONS AND METHODS FOR THE NEGATIVE SELECTION OF UNWANTED NUCLEIC ACID SEQUENCES
EP2771043A4 (en) ACTIVE RELEASE PROCEDURE
EP2560624A4 (en) THERAPEUTIC FORMULATION FOR REDUCED MEDICAMENT SIDE EFFECTS
EP2861227A4 (en) OMEGA-3 PENTAIC ACID COMPOSITIONS AND METHODS OF USE
EP2747563A4 (en) COMPOSITIONS AND METHODS FOR ORAL ADMINISTRATION OF MEDICINAL PRODUCTS
EP2915557A4 (en) Retinoic acid-MICRO NEEDLE
BR112013017169A2 (pt) composições farmacêuticas de ferro para administração oral
EP2827868A4 (en) PHARMACEUTICAL COMPOSITIONS WITH FATTY ACID ESTERS
FR2981572B1 (fr) Compositions pharmaceutiques d'acide ursodesoxycholique
EP2931313A4 (en) Solution Formulations of Genetically Engineered Anti- 23P19 Antibodies
EP2797933A4 (en) PROCESS FOR PREPARING 4-CHLORO-2-FLUOR-3-SUBSTITUTED PHENYLBORONIC ACID PINACOL ESTERS AND USE THEREOF
EP2842546A4 (en) PHARMACEUTICAL COMPOSITION WITH UNIT STRUCTURE FOR NUCLEIC ACID RELIEF
EP2717914A4 (en) DELAYED FORMULATIONS FOR THE ADMINISTRATION OF PROTEINS AND FOR THEIR MANUFACTURE
EP2928462A4 (en) METHOD FOR ADMINISTERING COMPOUNDS WITH DOCOSAPENTAIC ACID
EP2753336A4 (en) COMPOSITIONS WITH S-ADENOSYLMETHIONINE AND A BALLOIC ACID TESTER
EP2813488A4 (en) BASIC AMINO ACID DERIVATIVES WITH AMPHOTEEN IONES
EP3060220A4 (en) Compositions for oral administration of zoledronic acid or related compounds for treating disease
EP2825039A4 (en) INJECTABLE IBUPROFEN FORMULATION
ME03750B (me) Farmaceutska formulacija koja sadrži inozitol

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20150602

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20160504

RIC1 Information provided on ipc code assigned before grant

Ipc: C11B 5/00 20060101ALI20160428BHEP

Ipc: A61K 31/225 20060101AFI20160428BHEP

Ipc: A23D 9/00 20060101ALI20160428BHEP

Ipc: A61K 9/48 20060101ALI20160428BHEP

Ipc: A61K 31/202 20060101ALI20160428BHEP

Ipc: A23D 9/06 20060101ALI20160428BHEP

Ipc: A61K 31/40 20060101ALI20160428BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20200504

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20220701